Alnylam Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Alnylam Bundle
Actionable Strategy Starts Here
Alnylam’s BCG Matrix snapshot shows which RNAi assets are sprinting ahead and which need tougher choices — a quick way to see Stars, Cash Cows, Question Marks, and Dogs at a glance. This preview sketches competitive dynamics, but the full BCG Matrix breaks each product into quadrant-level detail, data-driven recommendations, and a clear capital-allocation roadmap. Buy the complete report to get editable Word and Excel files, actionable strategy, and a ready-to-present view you can use immediately.
Stars
Amvuttra (vutrisiran)
Amvuttra (vutrisiran) was FDA approved for hATTR polyneuropathy on 22 September 2022 and offers a subcutaneous dose every three months versus IV patisiran every three weeks, giving a clear convenience edge that drove rapid clinical uptake. It holds a strong share within the still-expanding hereditary ATTR polyneuropathy market. Alnylam continues to invest in launch activities, centers of excellence, and real‑world evidence to defend and extend the lead. If growth sustains, Amvuttra is positioned to graduate to cash cow status.
hATTR Franchise Lead
Alnylam effectively owns the RNAi segment in hATTR with ONPATTRO (FDA approval 2018) and AMVUTTRA (FDA approval 2022), setting the pace on outcomes and access across neurology and cardiology. Category growth and brand-switching tailwinds favor further uptake as clinicians consolidate on RNAi efficacy and dosing convenience. Prioritize investment to lock in cardiology co-management and expand global penetration through hub-and-spoke models. Protect switching dynamics by building payer-friendly, low-friction pathways and real-world evidence generation.
Givlaari Momentum
Givlaari momentum is driven by rising AHP patient identification; symptomatic AHP prevalence is roughly 1 per 100,000 and screening yields are improving. Givlaari, FDA-approved in 2019, showed a 74% reduction in annualized attack rate in ENVISION, underpinning durable access. Continue expanding diagnostic funnels and center coverage to capture untreated patients. Scale adherence programs to convert early starts into repeat dosing and predictable revenue.
Oxlumo Adoption
Primary hyperoxaluria type 1 affects ~1–3 per million and is underdiagnosed; Oxlumo (lumasiran) approved by FDA in Nov 2020 shows robust reduction in urinary oxalate, driving specialist pull and referral growth; expanding newborn and genetic screening can enlarge the treatable pool; tighten supply chain and hub services to shorten time-to-start and improve adherence.
- PH1 prevalence: 1–3/million
- FDA approval: Nov 2020
- Driver: strong efficacy → specialist demand
- Actions: screening expansion; supply/hub optimization
GalNAc RNAi Edge
GalNAc RNAi Edge: best‑in‑class hepatic delivery widely recognized—Alnylam’s RNAi portfolio includes Onpattro (patisiran, FDA 2018), Givlaari (givosiran, FDA 2019) and Amvuttra (vutrisiran, FDA 2022), demonstrating clinical and commercial validation; continued chemistry iterations and publications expand tissue reach and compound the lead as RNAi adoption grows.
- Tech lead: GalNAc hepatic targeting
- Validated: 3 Alnylam RNAi approvals by 2024
- Strategy: publish, iterate chemistry, broaden tissues
- Outcome: leadership → potential category dominance
GalNAc RNAi leaders drive high-growth rare-disease franchises; prioritize launches and payers
Alnylam’s Stars (Amvuttra, Oxlumo, Givlaari) show high growth and leading shares in expanding rare-disease niches, driven by GalNAc RNAi advantage and strong clinical uptake in 2024. Continued launch investment, real‑world evidence, and diagnostic expansion are prioritized to sustain growth and transition to cash cows. Protect access via payer pathways and hub optimization.
| Product | 2024 Rev ($M) | Market CAGR | Share |
|---|---|---|---|
| Amvuttra | ~600 | ~15% | ~60% |
| Oxlumo | ~250 | ~12% | ~50% |
What is included in the product
Detailed Word Document
BCG Matrix review of Alnylam’s portfolio with quadrant insights and invest/hold/divest guidance
Customizable Excel Spreadsheet
One-page Alnylam BCG Matrix that clarifies portfolio gaps, highlights resource shifts, and simplifies C-suite decisions
Cash Cows
Onpattro Legacy
Onpattro legacy remains a cash cow for Alnylam in 2024, driven by an established patient base and durable ex-US uptake that continues to generate recurring infusion revenue. Lower promotional intensity is possible as care pathways and specialist networks are mature. Focus is on optimizing gross-to-net and infusion operations to maximize free cash flow. Harvest strategy must manage cannibalization risk from subQ Amvuttra.
Leqvio Royalties
Leqvio royalties supply Alnylam a rising, high‑margin PCSK9‑siRNA cash stream with minimal opex drag; 2024 Leqvio global sales reached about $2.0bn, underpinning growing royalty receipts. Predictable royalties contribute steady free cash flow and margin expansion, funding R&D and pipeline bets. Alnylam supports partner uptake via post‑hoc data releases and policy advocacy to sustain volume and pricing, treating royalties as funding fuel.
Rare Disease Tail
Rare Disease Tail functions as a cash cow: stable, high‑value patients often generate >$100,000 per patient per year with multi‑year to lifelong durations, creating predictable revenue streams. Mature accounts require modest field effort and lower churn, letting SG&A per patient fall materially. Incremental infrastructure tweaks commonly lift margins 200–400 basis points, so milk the base while maintaining gold‑standard support.
Geographic Scale
Geographic scale: by 2024 Alnylam has established commercial access across the EU and Japan, with distribution and pricing know‑how streamlined to reduce launch friction and reimbursement timelines.
Low incremental cost per additional patient and repeatable operations improve cash generation; label harmonization and participating in tenders further compress marginal cost and accelerate uptake.
- EU/Japan commercial presence (2024)
- Low incremental cost per patient — operational repeatability
- Label harmonization + tenders boost margins
Manufacturing Leverage
Manufacturing leverage at Alnylam drives lower COGS through process know‑how and strict CMC discipline, contributing to improved gross margin versus earlier years; 2024 revenue reached roughly $3.2 billion, supporting scale benefits.
Shared platforms spread fixed costs across RNAi programs, and continuous improvement efforts have steadily boosted yield and margin, turning manufacturing into a quiet, dependable cash enhancer.
- CMC discipline reduces per-unit COGS
- Shared platforms amortize fixed costs
- Continuous improvement increases yield/margin
- 2024 revenue ~ $3.2B supports manufacturing scale
$2.0B royalties & >$100k/pt margins power $3.2B 2024
Onpattro remains a 2024 cash cow with steady infusion revenue; Amvuttra cannibalization must be managed. Leqvio royalties (~$2.0bn global sales 2024) provide high‑margin, predictable cash. Rare disease portfolios yield >$100k/patient/year with low SG&A. Manufacturing scale and 2024 revenue ~ $3.2B compress COGS and boost free cash flow.
| Metric | 2024 |
|---|---|
| Total revenue | $3.2B |
| Leqvio sales | $2.0B |
| Per‑patient RD | >$100k/yr |
What You See Is What You Get
Alnylam BCG Matrix
The file you’re previewing is the exact, final BCG Matrix you’ll receive after purchase. No watermarks or demo content — just a fully formatted, analysis-ready report crafted by strategy experts. Buy once and download immediately for editing, printing, or presenting to clients and teams.
Dogs
IV Patisiran Model
IV patisiran (Onpattro) requires weight-based IV infusions every 3 weeks for hATTR polyneuropathy, which creates significant infusion burden and drives switching to subcutaneous alternatives like vutrisiran (approved 2022) dosed every 3 months. The high administration overhead yields modest incremental revenue versus lower-burden rivals, making growth hard to achieve through marketing alone. Manage decline and redeploy field time to higher-growth subQ assets and specialty indications.
Maxed Micro‑Segments
Ultra‑niche cohorts for Alnylam products are essentially fully penetrated, with new patient flow at trickle level and commercial starts showing minimal growth in 2024. Chasing the last few starts is expensive given high acquisition and reimbursement costs per patient. Recommendation: hold accounts and avoid over‑investing in marginal uptake opportunities to protect margin and cash deployment.
Older Delivery IP
Older delivery IP at Alnylam relies on legacy chemistries that no longer differentiate, representing a shrinking strategic footprint as the company reported $2.34B product revenue in 2023 and shifted R&D toward GalNAc and next‑gen platforms. Maintenance costs persist without strategic upside, and these assets are competitively outclassed by newer LNP and GalNAc approaches. Sunset legacy IP and reallocate resources to next‑gen delivery to protect margins.
Non‑Core Infectious
Dogs:
Non‑Core Infectious
sits outside Alnylam’s 2024 near‑term sweet spot of hepatic genetic and cardio‑metabolic programs; infectious assets account for a single‑digit percent of the pipeline. Clinical complexity and tougher payer pathways curb commercial upside; Alnylam’s 2024 revenue ~$2.2B and >$1B R&D budget remain focused elsewhere. De‑prioritize unless a partner assumes development and commercialization.- Low share: single‑digit % of pipeline
- Low growth: limited near‑term commercial potential
- Clinical/payer risk: high
- Action: deprioritize unless partnered
Overlapping Assets
Alnylam in 2024 has 4 marketed RNAi products and over 20 pipeline programs; several internal programs compete for overlapping rare-disease pools, many with patient populations in the low thousands, creating portfolio clutter that dilutes clinical and commercial focus. Parallel spend across similar targets yields marginal incremental returns versus consolidated programs; prune or merge to reallocate capital to higher-return assets.
- 4 marketed products (2024)
- >20 pipeline programs (2024)
- Many targets: patient pools often low-thousands
- Prune/merge to free capital and improve ROI
Deprioritize infectious assets: single-digit % of pipeline; partner to shift cost
Dogs: non‑core infectious assets represent single‑digit % of pipeline in 2024 and carry high clinical/payer risk; Alnylam reported ~$2.2B product revenue and >$1B R&D in 2024, focusing on hepatic GalNAc programs. Limited growth prospects; deprioritize unless partnered to transfer cost and risk.
| Metric | 2024 | Action |
|---|---|---|
| Product revenue | ~$2.2B | Reallocate |
| R&D spend | >$1B | Protect core |
| Infectious share | Single‑digit % | Deprioritize/partner |
Question Marks
Zilebesiran (HTN)
Zilebesiran targets a massive market—~1.3 billion adults with hypertension and a global antihypertensive market ~35 billion USD (2024)—with clear unmet need in adherence and true 24/7 control as control rates are <20% globally. Early data are promising but commercial share is zero today; development will be capital intensive with payer proof of durable outcomes required. Strategy: invest heavily in outcomes/durability or partner for scale.
CNS RNAi Push
CNS RNAi Push targets new routes and new biology with high upside if delivery hurdles fall; by 2024 six siRNA therapies had FDA approval, underscoring platform potential. Technical risk remains meaningful given blood‑brain barrier challenges and lack of approved CNS siRNA to date. If tissue targeting clicks, program valuation could materially reset. Stage‑gate funding is tied to biomarker-driven go/no‑go milestones.
Ocular RNAi
Ocular RNAi targets multi‑billion dollar retinal franchises (market >US$10B in 2024) crowded by incumbents Roche, Novartis and Regeneron, so differentiation must be dosing ease and durability. Early traction will hinge on clean ocular safety; invest selectively and fast‑follow pivotal readouts and biomarker data.
Cemdisiran Combo
Cemdisiran combo sits as a Question Mark: complement diseases have clear biology and established premium pricing—eculizumab/ravulizumab range roughly $450k–$600k/year—so combos can carve defensible niches by improving durability or dosing. Success requires head‑to‑head or compelling real‑world evidence to shift prescriber economics. Back it conditional on visible partner momentum and clear POC.
- Addressable market: rare complement diseases (aHUS/PNH incidence ~0.5–2/million)
- Pricing leverage: ~$450k–$600k/yr for current C5 inhibitors
- Success trigger: H2H or RWE
- Decision: partner momentum required
New Cardio‑Metabolic
New Cardio‑Metabolic is a Question Mark: liver‑targeted RNAi can unlock large chronic markets (NAFLD/NASH prevalence ~25% globally in 2024), but competition is intense and payers demand hard outcomes; early biomarker wins (ALT, fibrosis scores) can rapidly translate to share and valuation inflection; fund winners, exit laggards quickly.
Hypertension ~1.3B/$35B; NAFLD ~25% — upside if durable
Question Marks: large addressable markets but high development/commercial risk — hypertension (Zilebesiran: ~1.3B adults, antihypertensive market ~$35B 2024, control <20%) and NAFLD (~25% prevalence 2024) offer upside if durability/outcomes proven; CNS/ocular RNAi show platform potential (six siRNA FDA approvals by 2024) but delivery/safety risks; cemdisiran combos need H2H/RWE vs C5 inhibitors (~$450k–$600k/yr).
| Program | Market size/metric (2024) | Key metric | Decision |
|---|---|---|---|
| Zilebesiran | ~1.3B adults; $35B | control <20% | Invest if outcomes |
| CNS RNAi | Platform; 6 approvals | BBB delivery | Stage‑gate |
| Ocular | >$10B | ocular safety | Selective |
| Cemdisiran | rare C5 diseases | $450k–$600k/yr | Partner conditional |
| Cardio‑Metabolic | NAFLD ~25% | biomarkers→outcomes | Rapid POC only |